Kiromic Biopharma Inc Cash Flow Conversion Efficiency
Kiromic Biopharma Inc cash flow conversion efficiency. Based on the latest financial reports, Kiromic Biopharma Inc (KRBP) has a cash flow conversion efficiency ratio of 0.290x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.65 Million) by net assets ($-12.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kiromic Biopharma Inc (2018–2024)
Cash flow conversion efficiency of Kiromic Biopharma Inc from 2018 to 2024. This chart illustrates how Kiromic Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Kiromic Biopharma Inc for real-time trading data and today's change.
Kiromic Biopharma Inc Cash Flow Conversion Ratio Explained
Kiromic Biopharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kiromic Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiromic Biopharma Inc ranked by their cash flow conversion efficiency. Also see Kiromic Biopharma Inc (KRBP) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TRELLUS HEALTH LS -0006
F:85Q
|
N/A |
|
Gangotri Textiles Limited
NSE:GANGOTRI
|
0.000x |
|
UMT United Mobility Technology AG
XETRA:UMDK
|
-0.046x |
|
ImmuPharma PLC
LSE:IMM
|
-2.979x |
|
Conygar Investment Co PLC
LSE:CIC
|
0.290x |
|
Rajvir Industries Limited
NSE:RAJVIR
|
-0.158x |
|
Rua Life Sciences PLC
LSE:RUA
|
0.004x |
|
TEVANO SYSTEMS HLDGS INC.
F:7RBA
|
N/A |
Annual Cash Flow Conversion Efficiency for Kiromic Biopharma Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Kiromic Biopharma Inc from 2018 to 2024. Review how financially flexible is Kiromic Biopharma Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.59 Million | $-19.46 Million | 1.546x | -33.57% |
| 2023-12-31 | $-9.12 Million | $-21.23 Million | 2.327x | -43.41% |
| 2022-12-31 | $-5.77 Million | $-23.75 Million | 4.112x | +652.82% |
| 2021-12-31 | $27.32 Million | $-20.32 Million | -0.744x | -37.95% |
| 2020-12-31 | $11.36 Million | $-6.13 Million | -0.539x | +63.38% |
| 2019-12-31 | $1.98 Million | $-2.91 Million | -1.472x | +81.86% |
| 2018-12-31 | $265.30K | $-2.15 Million | -8.115x | -- |
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more